Edwards Lifesciences Corporation $EW Holdings Trimmed by Jennison Associates LLC

Jennison Associates LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.2% during the first quarter, Holdings Channel.com reports. The fund owned 13,066,274 shares of the medical research company’s stock after selling 714,241 shares during the quarter. Jennison Associates LLC’s holdings in Edwards Lifesciences were worth $1,046,347,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 39.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after purchasing an additional 648,870 shares in the last quarter. Central Pacific Bank Trust Division acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $775,000. Sivik Global Healthcare LLC acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $2,984,000. Finally, Norges Bank bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $803,686,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 2.4%

EW stock opened at $85.72 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market capitalization of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company’s 50 day simple moving average is $87.34 and its 200-day simple moving average is $83.94.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the business posted $0.64 EPS. The company’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,577 shares of company stock worth $3,855,527 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Robert W. Baird boosted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research report on Wednesday, April 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.